BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  INmune Bio Announces $13.0 Million Registered Direct Offering

  September 16, 2024

   · 

  5 min read
• Press Releases

  Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US

  September 16, 2024

   · 

  2 min read
• Press Releases

  RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

  September 16, 2024

   · 

  16 min read
• Press Releases

  KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

  September 16, 2024

   · 

  19 min read
• Press Releases

  Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

  September 16, 2024

   · 

  8 min read
• Press Releases

  Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

  September 16, 2024

   · 

  9 min read
• Press Releases

  Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

  September 16, 2024

   · 

  3 min read
• Press Releases

  SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

  September 16, 2024

   · 

  4 min read
• Press Releases

  Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

  September 16, 2024

   · 

  19 min read
• Press Releases

  Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

  September 16, 2024

   · 

  13 min read